Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameGaush Meditech
Stock Code02407
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities經銷廣泛的眼科醫療設備及耗材,涵蓋眼科七個亞專科,並向最終客戶提供相關技術服務;產品組合包括品牌夥伴經銷產品及自有產品,為中國眼科醫療器械市場最大國內參與者。
Listing Date2022-12-12
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市東城區東直門南大街11號中匯廣場A座1901室
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場2座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.gaush.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 51.40 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 5,140
Par ValueTo be extracted
Offer Period2022-11-30 to 2022-12-05
Global Offering Shares13,068,600 shares
HK Public Offer Shares (Initial)1,307,000 shares (10.0%)
Public Offer Lots (Initial)13,070lots (Pool A6,535lots,Pool B6,535lots)
International Placing Shares (Initial)11,761,600 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO147,934,869 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share48.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 671,726,040

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 5,140
2 lots 200 HK$ 10,280
3 lots 300 HK$ 15,420
4 lots 400 HK$ 20,560
5 lots 500 HK$ 25,700
6 lots 600 HK$ 30,840
7 lots 700 HK$ 35,980
8 lots 800 HK$ 41,120
9 lots 900 HK$ 46,260
10 lots 1,000 HK$ 51,400
15 lots 1,500 HK$ 77,100
20 lots 2,000 HK$ 102,800
25 lots 2,500 HK$ 128,500
30 lots 3,000 HK$ 154,200
35 lots 3,500 HK$ 179,900
40 lots 4,000 HK$ 205,600
50 lots 5,000 HK$ 257,000
60 lots 6,000 HK$ 308,400
70 lots 7,000 HK$ 359,800
80 lots 8,000 HK$ 411,200
100 lots 10,000 HK$ 514,000
200 lots 20,000 HK$ 1,028,000
300 lots 30,000 HK$ 1,542,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,000 lots 100,000 HK$ 5,140,000
1,500 lots 150,000 HK$ 7,710,000
2,000 lots 200,000 HK$ 10,280,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 776.3M
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +1148%

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,603,852,267
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣191.6百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Revenue 289,142245,412
Cost of sales -107,670-121,889
Gross profit 181,472123,523
Other income and gains, net 301314
Selling and distribution expenses -26,128-51,114
Administrative expenses -16,116-17,688
Operating profit 121,70736,012
Net finance costs -479-668
Profit before tax 121,22835,344
Income tax expense -22,659-9,979
Profit for the year 98,56925,365
Profit attributable to owners 98,56925,365
Balance Sheet
Item 20192020
Cash and cash equivalents 104,478105,978
Trade and bills receivables 30,63723,256
Inventories 40,79743,544
Total current assets 193,036216,498
Total assets 263,352300,945
Total current liabilities 25,03472,040
Total liabilities 134,128142,387
Total equity 129,190158,558
Equity attributable to owners 129,182158,550
Cash Flow Statement
Item 20192020
Net cash from operating activities 78,39586,857
Net cash from investing activities -16,394-80,550
Net cash from financing activities -4,952-6,215
Net increase in cash 57,04992
Depreciation of PP&E 1,7552,860
Depreciation of right-of-use assets 4,9685,705
Amortisation of intangible assets 639845
Purchase of PP&E -15,181-5,052
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 51.4
First Day OpenHK$ 51.2
First Day Change-90.47%
First Day Volume521800.0
First Day Turnover26102400.0
Use of Proceeds
1、約38.2%或108.1百萬港元將于上市后兩年內用于提高我們的研發能力及加速我們的專利商業化; 2、約29.0%或82.1百萬港元將于上市后兩年內用于提高我們的產能及增強我們的制造能力; 3、約9.5%或26.9百萬港元將于上市后兩年內用于透過聘請專門從事眼科醫療器械銷售及營銷的人員; 4、約10.6%或30.0百萬港元將用作我們的營運資金及一般企業用途; 5、約12.7%或36.0百萬港元將用于償還我們就收購泰靚所產生利率為5%的夾層融資貸款。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 海通国际资本有限公司 CE ADQ859
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806
Joint Bookrunners (5)
Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806 Daiwa Capital Markets Hong Kong Limited CE AAB639 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940
Joint Lead Managers (7)
Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806 Daiwa Capital Markets Hong Kong Limited CE AAB639 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940 迈时资本有限公司 CE BNO600 SINOMAX SECURITIES LIMITED CE AHC207

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 CL Kiwi Holding Ltd. 39,135,960 HKD — 5.83% — 6 months 2023-06-12
2 江苏中德服贸产业投资基金(有限合伙) 15,260,660 HKD — 2.27% — 6 months 2023-06-12
3 无锡高视创业投资合伙企业(有限合伙) 7,432,440 HKD — 1.11% — 6 months 2023-06-12
4 无锡视高股权投资合伙企业(有限合伙) 262,217,100 HKD — 39.04% — 6 months 2023-06-12

Directors & Management

PositionChinese nameEnglish Name
Chairman高鐵塔—
Company Secretary李文奇、梁瑞冰—
No director data available.

Major Shareholders

Major Shareholders & Holdings高鐵塔通過GT HoldCo持股42.76%;OrbiMed Asia持股12.19%;Cuprite Gem持股7.69%(緊隨全球發售完成後,假設超額配股權未獲行使)
About this page

This page shows Gaush Meditech (02407) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect